ArticleChemical science2026
Fully protected pyrophosphates
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural oligomers containing phosphodiester linkages, such as DNA and RNA oligomers, are readily accessible through the phosphoramidite P(iii) approach. However, the repetitive introduction of pyrophosphates into an oligomeric backbone, as found in poly-ADP-ribose, remains challenging. The most effective method to date relies on P(iii)-P(v) coupling, in which a phosphate monoester is linked with a phosphoramidite, facilitating chain elongation of the biopolymer following the oxidation of the P(iii)-P(v) intermediate. This anionic and nucleophilic intermediate limits the chain length that can be achieved. To overcome this limitation, we designed a methodology based on P(v)-P(v) chemistry, where a phosphodiester is coupled to a protected and activated P(v) donor. To this end, the Atherton-Todd oxidation of H-phosphonates is utilised to generate an electrophilic halophosphate, which is then coupled with a phosphodiester to yield a fully protected pyrophosphate species. The chemistry was optimised to balance the reactivity and stability of the coupling partners and the product by introducing the
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.